In today’s dynamic Pharma and Life Sciences environment, AI has the potential to be a powerful driver of innovation, efficiency, and improved patient outcomes. But while investment is high, many organisations are yet to translate that promise into real-world value.
At Baringa, we’ve worked with pharma companies unlock the true value of AI focussing on four key areas: getting data right, implementing appropriate governance, embedding organisational trust and upskilling teams to drive adoption. By doing so, pharma can leverage AI to accelerate both scientific and commercial outcomes.
But we know that instilling an AI and data-first culture within an organisation is challenging. It requires transparent communication, innovation, and addressing issues like algorithm transparency, compliance concerns and job displacement fears. Leadership plays a pivotal role in shifting a company's mindset to embrace AI and foster a culture of creativity.
By working with the leaders in your organisation, we can help you implement the changes needed to maximise the value of AI.
Unlocking the business value from AI in Pharma
Artificial Intelligence (AI) holds tremendous promise across the pharmaceutical and life sciences industry. Estimates suggest that, if scaled effectively, AI could generate up to $254 billion in additional annual operating profits for pharma companies globally by 2030. Explore four areas where life sciences companies frequently fall short – and outline the critical enablers to achieving both scale and value from AI investments.
Our Experts
Is digital and AI delivering what your business needs?
Digital and AI can solve your toughest challenges and elevate your business performance. But success isn’t always straightforward. Where can you unlock opportunity? And what does it take to set the foundation for lasting success?